Pfizer’s pricing deal with the Trump administration, which won the company a three-year exemption from sector-specific ...

Discover why Pfizer Inc. is rated a Strong Buy with 33% upside, robust dividends, and growth prospects ahead. Click for my updated look at PFE stock.

Concerns about the company's future growth are likely keeping investors away.

Cogent Biosciences, Inc. stock soars after bezuclastinib's strong Phase 3 results in GIST. Click for my updated look at COGT ...

As you might expect, the competition to win a share of the expanding GLP-1 market is fierce right now, with giants Novo ...

The first thing that comes to mind when we speak about the S&P 500 is the biggest tech companies, high valuations, and ...

The Metsera deal is about winning the obesity drugs' market that’s expected to reach US$100 billion by 2030. Read more at ...

Investing.com - U.S. stock futures rose sharply Monday after the Senate voted in favor of a bill aimed at ending the ...

Pfizer's agreement to buy Metsera just adds to the 83 healthcare deals counted by Goldman Sachs that were above $100 million ...

Markets have turned upbeat amid optimism that the 39-day US shutdown could soon come to an end, after a weekend of dealmaking in Washington. A new bill quickly advanced in a key S ...

While the process of re-opening government could yet take several days and the proposed Senate bill would only fund ...

Major U.S. equities indexes rose Monday afternoon amid optimism Congress could soon agree on a spending plan to end the ...